Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi toward innovative medicines.
July 7, 2014
We plan to host a series of online “RNAi Roundtables” during July and August, at which Alnylam scientists and key clinical collaborators will review recent progress from several “Alnylam 5×15” programs and discuss the related disease areas.
Patisiran and ALN-TTRsc for the treatment of Transthyretin-Mediated Amyloidosis (ATTR)
Tuesday, July 15: 12:30 – 2:00 p.m. ET
- Jared Gollob, M.D., Vice President, Clinical Research
- Moderator: John Maraganore, Ph.D., Chief Executive Officer
- Guest Speaker: Philip N. Hawkins, M.B., B.S., Ph.D., FRCP, Professor of Medicine, National Amyloidosis Centre, University College London Medical School
To register and access the webcast for this event, please click here.